indapamide对患者尿钙排泄的影响,没有尿石病。

文章的细节

引用

复制到剪贴板

Ceylan K, Topal C, Erkoc R, Sayarlioglu H, S, Yilmaz Y,多根E, Algun E, Gonulalan H

indapamide对患者尿钙排泄的影响,没有尿石病。

安Pharmacother。2005年6月,39 (6):1034 - 8。doi: 10.1345 / aph.1E544。Epub 2005年4月19日。

PubMed ID

15840731 (在PubMed

]

文摘

背景:Indapamide是一种抗高血压药与噻嗪类相似,但有一些不同的效果。thiazide-like和噻嗪类利尿剂是有用的在预防复发性尿石形成由于hypocalciuric效果。目的:确定hypocalciuric和其他影响某些indapamide 1.5毫克的实验室参数在不同的患者群体。方法:四组病人招募了来自泌尿外科和肾脏学门诊部门正在经历non-hypercalciuric尿石病(组1),特发性高钙尿(组2),与高钙尿尿石病(组3)和原发性高血压(4组),所有患者空腹血清尿酸、钙、钠、钾、胆固醇、甘油三酯、甲状旁腺激素(素值,和早上第二位尿钙和肌酐水平与indapamide治疗前和治疗8周后评估。结果:尿钙排泄减少大大在所有组:第1组从0.10 + / - 0.02到0.07 + / - 0.03(意思是+ / -标准差;减少30%;p < 0.001),组2从0.30 + / - 0.15到0.15 + / - 0.10(减少50%;p < 0.001),组3从0.35 + / - 0.15到0.20 + / - 0.10(减少43%;p < 0.001),组4从0.10 + / - 0.03到0.08 + / - 0.02(减少20%;p < 0.0010)。 These results should be interpreted with caution since no control group was included in this study. Mean serum uric acid and triglyceride levels were significantly increased, and mean PTH and potassium levels and diastolic and systolic blood pressure were significantly decreased in all groups. Few temporary adverse effects, such as dizziness and fatigue, were noticed and none of them caused discontinuation of treatment. CONCLUSIONS: Indapamide 1.5 mg/day is effective in decreasing calciuria in patients with non-hypercalciuric urinary stone disease, idiopathic hypercalciuria, urinary stone disease with hypercalciuria, and essential hypertension. This could be achieved with few adverse effects similar to those of thiazides and indapamide 2.5 mg. Indapamide decreased the PTH levels in all groups. Long-term clinical benefits of these effects should be evaluated prospectively with further randomized studies.

DrugBank数据引用了这篇文章

药物

Indapamide